SynaffixSynaffixSynaffixSynaffix
  • About
  • Technology
    • Technology Snapshot
    • GlycoConnect™
    • HydraSpace™
    • toxSYN™ Payloads
    • Bispecific Antibodies
  • Leadership
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Partnerships
  • News & Media
  • Careers
  • Contact
  • About
  • Technology
    • Technology Snapshot
    • GlycoConnect™
    • HydraSpace™
    • toxSYN™ Payloads
    • Bispecific Antibodies
  • Leadership
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Partnerships
  • News & Media
  • Careers
  • Contact

Synaffix Wins ‘Best ADC Platform Technology’ Award

  • September 22, 2020/
  • Posted By : admin/
  • 0 comments /
  • Under : News, Press Releases

Read More


Competitive New Data from ADCs Based on Synaffix Proprietary Exatecan Linker-Payload

  • September 16, 2020/
  • Posted By : admin/
  • 0 comments /
  • Under : News, Press Releases

Read More


Synaffix Announces Third Deal Expansion by ADC Therapeutics

  • July 23, 2020/
  • Posted By : admin/
  • 0 comments /
  • Under : News, Press Releases

Read More


1234Next ›Last »
UPCOMING EVENTS

Bio Europe Spring

22-25 Mar 2021

Online

DOWNLOADS

› Corporate Fact Sheet


› AACR 2020: Cell Engagers


› Nature Company Profile


› 2018 HydraSpace Publication

TWITTER
  • We are so proud and grateful to have just received the ‘Best ADC Platform Technology’ award at the @HansonWade… https://t.co/mGZTnKyUA9 6 months ago
  • RT @Instinctif_HLS: .@Synaffix Sees Competitive Early In Vivo Data from #ADCs Based on Proprietary Exatecan Linker-Payload… https://t.co/MFTt9eTzVa 6 months ago
Follow @synaffix
Copyright Synaffix BV . All Rights Reserved